BofA Lifts Enovix Target To $7 As Honor Drops Killer Battery Test

BofA Securities lifted its price target on Enovix Corporation to $7 from $6 on Tuesday, May 5, 2026, after the silicon-anode battery maker filed an 8-K saying it had reached alignment with Honor on a new qualification framework for its AI-1 smartphone cell. The rating stayed at Neutral. Enovix shares trade near $6.29, giving it a market cap around $1.34 billion.

The short version: Honor agreed to drop the 0.7C accelerated cycle-life test that Enovix could not pass, and to use a silicon-specific protocol instead. BofA reads that as confirmation Enovix won’t have to reformulate its battery to keep the deal alive, with details expected on the May 13 earnings call.

What BofA Actually Changed, And Why It Matters Now

The new $7 target is a 16.7% bump. It still sits at the low end of the Street, where the average 12-month target runs near $14.45 and the high call reaches $25, per Enovix consensus data on StockAnalysis. BofA kept its underlying estimates unchanged. The move is sentiment, not numbers.

Analyst Bill Peterson at JPMorgan went the other way the same week. He pulled his $6 December 2026 target and cut Enovix to Underweight from Neutral, arguing the volume ramp will keep slipping and that Enovix’s energy-density lead is narrowing faster than the market thinks.

So the two desks looked at the same 8-K and reached opposite conclusions. BofA sees an unblocked path. JPMorgan sees a delayed ramp into a market where silicon-carbon incumbents are catching up.

The Test That Was Killing The Deal

For most of 2025, one specific test kept Enovix’s smartphone story stuck. Honor uses a 0.7C accelerated cycle-life protocol, an industry-standard proxy that runs cells hard to estimate long-term life in weeks rather than years. Enovix’s AI-1 cells passed nearly every requirement, but not that one.

CEO Raj Talluri described the physics on the Q4 2025 earnings call. “When you change technology from graphite batteries to silicon anode batteries, silicon anode batteries behave differently when you discharge them very fast, in this 0.7C,” Talluri said, per the Motley Fool transcript of the Enovix Q4 2025 call. “Honor and other smartphone customers understand that. They realize that this test is a proxy and an accelerated test and not a true test.”

Internal Enovix data showed AI-1 cells exceed 1,000 cycles at 0.2C, the slower rate closer to how phones actually charge. Management had floated three exits: get the customer to accept 0.2C, agree on a new accelerated protocol, or change the chemistry. The 8-K confirms door number two.

Honor Is Not Just A Customer. It Is The Competition.

Here is the part most coverage skipped. Honor already builds its own silicon battery, and it is winning awards for it.

At MWC 2026 in Barcelona, Honor took home the GLOMO for Best Disruptive Device Innovation for the silicon-carbon Blade Battery in the Magic V6. The chemistry uses 25% silicon mixed into a carbon matrix, with a next-generation cell shown at the same event pushing silicon content to 32% and energy density to 985 Wh/L. Enovix’s headline number on AI-1 is 935 Wh/L, validated by a third party as the highest commercial figure for a 100% silicon anode.

On paper, Honor’s roadmap cell is denser. The catch is durability and form factor. Silicon-carbon hits a ceiling around 700 to 985 Wh/L because the silicon load is capped by swelling. Enovix’s 3D architecture mechanically constrains a pure silicon anode and limits cell-thickness swell to under 2%, which is why the company can sell a 7,350 mAh cell with fast-charge headroom for on-device AI.

Honor’s silicon-carbon Blade is an evolutionary win on density. Enovix’s AI-1 is a structural bet that 100% silicon scales further, charges harder, and survives more cycles once OEM testing catches up to the new chemistry.

That framing changes how you read the qualification deal. Honor is not adopting Enovix because it lacks a battery. Honor wants a second source with a different physics envelope, one that pure silicon-carbon cannot match for AI workloads that hammer the cell at high discharge rates.

The Numbers Heading Into May 13

Enovix reports first-quarter 2026 results after the close on Wednesday, May 13. The Q4 2025 print, posted in late February, set the baseline.

• $11.3 million in Q4 2025 revenue, up 16% year over year and above the $10.5 million top of guidance.
• $31.8 million in full-year 2025 revenue, a 38% increase, driven by defense and industrial shipments out of Enovix’s full-year 2025 results release from its Korean subsidiary Routejade.
• 23% non-GAAP gross margin for the full year, with Q4 hitting 26%.
• $621 million in cash, equivalents and marketable securities at year-end, with a $75 million buyback authorized.

For the first quarter the company guided revenue of $6.5 million to $7.5 million, a sharp sequential drop the company tied to seasonal defense program timing rather than a smartphone signal. Non-GAAP operating loss guidance runs $29 million to $32 million.

BofA said it will be listening for one thing above all else: whether the new test framework changes expected revenue for fiscal 2026 or fiscal 2027. Analysts polled by InvestingPro still see 28% revenue growth this year, layered on top of last year’s 38%, but profitability is not in the model.

The Hire Buried In The Same 8-K

The same filing that announced the Honor framework also disclosed a new sales chief. Enovix appointed Steve Bakos as Senior Vice President of Worldwide Sales, a newly created role reporting to Chief Business Officer Samira Naraghi. Bakos arrives from Infineon Technologies, where he ran corporate account sales for global accounts including Apple.

Read that hire next to the customer list. Enovix already says it is engaged with seven of the top eight global smartphone OEMs. The Apple-account pedigree on Bakos’s resume is not a coincidence on a week when management is trying to convince Wall Street that the qualification door is now open beyond Honor.

The Real Risk Is The Factory, Not The Lab

Even if the May 13 call confirms a clean path through Honor’s new test, the harder constraint is in Penang, Malaysia. Enovix’s Fab2 line runs nine process steps. Eight of them yield above 80%. The ninth, laser dicing of the electrode ribbons, runs slower than the rest of the line and gates throughput.

Talluri laid it out plainly on the Q4 call. The line is functional. The dicing step is the rate limiter. Engineers are testing multiple laser types, and there is a Plan B involving a custom mechanical punching tool. The smartphone qualification process with Honor includes an explicit contingency for an optimization path that would shift production ramp into the second half of 2026.

What Could Go Right

If the new silicon-specific protocol holds, AI-1 cells start shipping into Honor handsets in the back half of 2026, with the smart-eyewear opportunity, where qualification thresholds are lower, ramping in parallel. Enovix has already sampled multiple major eyewear OEMs and laid out a $400 million eyewear battery TAM by 2030 in Seeking Alpha’s coverage of Enovix’s smart eyewear pipeline.

What Could Go Wrong

The new test takes longer to run by design. BofA flagged that explicitly. If results come in flat against the longer protocol, or if Penang dicing yields stay stuck, Enovix burns more of its $621 million cushion before a single dollar of smartphone revenue books. Defense shipments will keep the lights on. They will not justify a $1.34 billion market cap.

How The Stock Sets Up Into Earnings

Shares are flat year to date at the $6.29 level, well off the 2024 highs. The setup into Wednesday’s print is asymmetric. A clean walk-through of the Honor framework, plus any color suggesting fiscal 2026 revenue does not slide further, would close the gap between BofA’s $7 floor and the $14.45 Street average. A deferred ramp, or hedged language on the new test timeline, would give JPMorgan’s downgrade thesis the data it needs.

Notice what is not in any analyst note this week: a price target tied to smart eyewear or defense alone. The entire equity story is still keyed to one Chinese smartphone OEM signing off on a battery format that has never shipped before in a phone.

Frequently Asked Questions

What did BofA actually do to Enovix’s price target?

BofA Securities raised its price target on Enovix from $6 to $7 on May 5, 2026, while keeping a Neutral rating. The bump was 16.7%. BofA did not raise its underlying earnings or revenue estimates. The move was driven entirely by the 8-K disclosing a new qualification framework with Honor. BofA says it will reassess the model after Enovix’s Q1 2026 earnings call on May 13.

Why was the 0.7C cycle-life test such a big deal?

The 0.7C accelerated test runs a battery hard to estimate long-term cycle life quickly. Enovix’s pure silicon-anode AI-1 cells exceed 1,000 cycles at the slower 0.2C rate but were missing the 0.7C target. Without an alternate protocol, Honor could not formally qualify the cell, which would have blocked any 2026 smartphone revenue. The new silicon-specific test framework removes that block without forcing Enovix to change its chemistry.

Is Honor not already using silicon batteries?

Honor uses silicon-carbon batteries, which blend roughly 25 to 32% silicon into a carbon matrix. The Magic V6 won a GLOMO at MWC 2026 for that design. Enovix’s AI-1 uses a 100% active silicon anode in a patented 3D architecture. The two technologies are not interchangeable. Honor wants Enovix as a second source for AI-class workloads where silicon-carbon hits a density and discharge ceiling.

When does Enovix report Q1 2026 earnings?

Enovix reports first-quarter 2026 results after the market close on Wednesday, May 13, 2026, with a conference call to follow. Guidance issued in February calls for Q1 revenue of $6.5 million to $7.5 million and a non-GAAP operating loss of $29 million to $32 million. BofA, JPMorgan, and Oppenheimer have all said they will be listening specifically for updates on the new Honor test framework and any change to fiscal 2026 and fiscal 2027 revenue assumptions.

Should I treat this as a buy signal on ENVX?

No. BofA explicitly kept a Neutral rating, citing manufacturing hurdles, qualification timing, and expected negative margins and cash flow for several years. JPMorgan moved the other direction with an Underweight downgrade. Wall Street’s range on the stock spans $6 to $25, which signals genuine disagreement about commercial timing. Wait for the May 13 call before drawing conclusions, and read the full risk profile in the company’s most recent 10-K.

The lab story is closer to a resolution than it has been in two years. The factory story is not. Enovix shareholders have spent most of 2026 watching the same gap between technology validation and commercial scale, and Wednesday’s call is the next chance to find out which side wins. BofA’s $7 print is a vote that the gap is closing. JPMorgan’s downgrade is a vote that it is not closing fast enough.

Disclaimer: This article reports on analyst price targets, company filings, and earnings guidance and does not constitute investment advice. Equities in early-commercialization battery companies carry significant risk, including manufacturing delays, qualification failures, and substantial cash burn. Price targets cited are accurate as of publication on May 9, 2026, and may change without notice. Readers should consult a licensed financial advisor and review Enovix’s most recent SEC filings before making any investment decision.